Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

By M. Ghielmini, S. F. Schmitz, S. Cogliatti, G. Pichert, J. Hummerjohann, Ursula Waltzer, M. Fey, D. Betticher, G. Martinelli, F. Peccatori and 9 more. Blood, 2004

595 citations recorded by the source corpus.

Subfields: Immunology, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/bbed213fdb9bfeae99b5b6bb63000c5ea1a37d5a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Salomone
2. L. Falzone
3. M. Libra

Citations in the corpus

• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “Others studies showed that high doses of Rituximab were well-tolerated by patients affected by indolent NHL and were able to induce the remission of pathology in a high percentage of patients (Ghielmini et al., 2004; Hainsworth et al., 2005).”